Achieve Life Sciences, Inc.
ACHV
NASDAQ·Healthcare·Biotechnology·Mkt cap $871.6M
$8.49
▲ +2.17%
P/E
-5.48
Mkt Cap
$871.6M
52-Wk Range
$2.62–$8.64
52-Week Range
$2.62 - $8.64
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 189.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Plant-based natural compound with established safety profile
- Strategic partnerships with established pharmaceutical and academic institutions
- First-mover advantage in North American cytisinicline market
- Addressing underserved smoking cessation market with novel mechanism of action
Bear Case
1 risk
- High volatility (beta 2.3). Larger-than-normal price swings expected.
Growth
Stable outlook
Expanding clinical trial data and FDA approval pathway
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+54.9% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ACHV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 11, 2026
Reported EPS of -$0.80 vs -$0.16 consensus (-385.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-385.2%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Morgan Stanley · Aug 13, 2026
vs Industry
How ACHV stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related